Pharma stocks in India offer investors exposure to domestic healthcare demand, generic medicines, specialty drugs, biotechnology and pharmaceutical contract manufacturing. Companies such as Sun Pharma, Divi's Laboratories, Cipla, Dr. Reddy's Laboratories, Lupin and Torrent Pharmaceuticals operate across different segments, making their financial performance and growth opportunities different.
India's pharmaceutical exports reached approximately US$31.12 billion in FY26, compared with US$30.47 billion in FY25, reflecting growth of around 2.1%. However, the latest Q2 FY27 results show that revenue growth has not translated into higher profitability for every pharmaceutical company.
Identifying the best pharma stocks in India in 2026 requires more than comparing share prices or market capitalisation. Investors must assess business models, revenue growth, operating margins, cash flow, regulatory risks and valuations.
This article examines 14 major listed pharmaceutical companies, their Q2 FY27 financial performance, business drivers, investment risks and the factors investors should monitor next.
Table of Contents
- Best Pharma Stocks in India 2026: Full Stock List
- Indian Pharmaceutical Industry Overview 2026
- Detailed Analysis of Leading Pharma Stocks
- Pharma Stocks by Business Model
- Key Factors Driving Pharma Stocks in India
- Major Risks in Pharmaceutical Stocks
- How to Evaluate Pharma Stock Valuations
- What Q2 FY27 Results Mean for Investors
- Which Pharma Stocks Should Investors Watch in 2026?
- What Should Investors Monitor in Q3 FY27?
- Conclusion
- FAQs on Best Pharma Stocks in India
India has several leading pharmaceutical companies operating across domestic medicines, global generics, APIs, biotechnology and contract manufacturing. These companies differ in their business models, market presence and financial performance.
Here is a list of 14 major pharma stocks in India that investors can explore in 2026:
- Sun Pharmaceutical Industries
- Aurobindo Pharma
- Dr. Reddy's Laboratories
- Zydus Lifesciences
- Lupin
- Cipla
- Torrent Pharmaceuticals
- Alkem Laboratories
- Biocon
- Mankind Pharma
- Glenmark Pharmaceuticals
- Divi's Laboratories
- Ipca Laboratories
- Laurus Labs
These companies represent different segments of the Indian pharmaceutical industry. The list is intended for research and is not a ranking or investment recommendation.
Pharma Stocks Q2 FY27 Financial Comparison
The table presents consolidated financial performance for the quarter ended 30 September 2026.
| Company |
Q2 FY27 Revenue (₹ Cr) and YoY Growth |
| Sun Pharma |
₹16,100 Cr (+11.8%) |
| Aurobindo Pharma |
₹10,263 Cr (+23.9%) |
| Dr. Reddy's |
₹8,670.8 Cr (−1.5%) |
| Zydus Lifesciences |
₹7,909.6 Cr (+29.2%) |
| Lupin |
₹7,827.3 Cr (+11.1%) |
| Cipla |
₹7,404 Cr (−2.4%) |
| Torrent Pharma |
₹4,979 Cr (+50.8%) |
| Alkem Laboratories |
₹4,552 Cr (+13.8%) |
| Biocon |
₹4,389 Cr (+2.2%) |
| Mankind Pharma |
₹4,338 Cr (+17.3%) |
| Glenmark Pharma |
₹4,247.3 Cr (−29.8%) |
| Divi's Laboratories |
₹3,676 Cr (+35.4%) |
| Ipca Laboratories |
₹2,909.9 Cr (+13.8%) |
| Laurus Labs |
₹2,206 Cr (+33.0%) |
Sources: Company Q2 FY27 financial statements, earnings releases, investor presentations and NSE filings.
Note: Sun Pharma's ₹16,100 crore represents company-reported sales. Its statutory consolidated revenue from operations was ₹16,198.71 crore. Lupin's ₹7,827.3 crore includes other operating income, while its product sales were ₹7,785.5 crore.
Pharma Stocks Q2 FY27 Profitability Comparison
Revenue growth becomes more meaningful when evaluated alongside operating profitability and reported earnings.
Pharma Stocks Q2 FY27 EBITDA Margin Comparison
|
Company
|
EBITDA Margin
|
|
Sun Pharma
|
29.3%
|
|
Aurobindo Pharma
|
21.0%
|
|
Dr. Reddy's
|
20.6%
|
|
Zydus Lifesciences
|
24.0%
|
|
Lupin
|
27.9%*
|
|
Cipla
|
18.7%
|
|
Torrent Pharma
|
33.5%
|
|
Alkem Laboratories
|
22.5%
|
|
Biocon
|
20.0%
|
|
Mankind Pharma
|
27.1%
|
|
Glenmark Pharma
|
20.3%
|
|
Divi's Laboratories
|
Not separately disclosed
|
|
Ipca Laboratories
|
23.0%
|
|
Laurus Labs
|
34.5%
|
Pharma Stocks Q2 FY27 Reported PAT Comparison
|
Company
|
Reported PAT (₹ Cr)
|
|
Sun Pharma
|
1,988.5
|
|
Aurobindo Pharma
|
1,124
|
|
Dr. Reddy's
|
925
|
|
Zydus Lifesciences
|
925.5
|
|
Lupin
|
1,155.3
|
|
Cipla
|
878
|
|
Torrent Pharma
|
534
|
|
Alkem Laboratories
|
675.3
|
|
Biocon
|
41
|
|
Mankind Pharma
|
716
|
|
Glenmark Pharma
|
263.8
|
|
Divi's Laboratories
|
1,127
|
|
Ipca Laboratories
|
375.1
|
|
Laurus Labs
|
441
|
Important points for investors:
-
Sun Pharma: Reported PAT was ₹1,988.5 crore, while adjusted PAT was ₹3,162 crore due to exceptional charges.
-
Torrent Pharma: Revenue growth of 50.8% included the merged JB Chemicals business. Its base business grew 18%.
-
Glenmark: Reported revenue declined 29.8%, but like-for-like revenue grew approximately 20%.
-
Lupin: Its 27.9% EBITDA margin is calculated on product sales and includes forex and other income.
-
Divi's Laboratories: Consolidated revenue from operations was ₹3,676 crore, while total income stood at ₹3,770 crore.
EBITDA definitions are not completely standardised across companies, and Dr. Reddy's reports under IFRS. Therefore, the margins should be treated as indicative rather than perfectly comparable.
The stock list is not a ranking based on expected returns, valuation or investment attractiveness.
What Do the Latest Pharma Results Indicate?
Q2 FY27 financial results reveal different trends across Indian pharmaceutical businesses.
Aurobindo Pharma, Laurus Labs and Divi's Laboratories reported strong revenue and profit growth. Meanwhile, Zydus Lifesciences and Torrent Pharma recorded substantial revenue growth but weaker reported profitability.
Cipla and Dr. Reddy's experienced pressure in their North American operations, while Sun Pharma benefited from growth in domestic formulations and innovative medicines.
These differences highlight why identifying good pharmaceutical stocks requires analysing the source of growth, not merely the percentage increase in quarterly revenue.
India is one of the world's largest pharmaceutical manufacturing centres, supported by its generic medicine production, established manufacturing infrastructure, domestic healthcare market and export relationships.
The sector includes companies manufacturing affordable generic medicines as well as businesses developing complex generics, biologics, specialty treatments and pharmaceutical ingredients.
Indian Pharmaceutical Industry Statistics
| Indicator |
Latest Available Data |
| Global pharmaceutical production ranking |
3rd by volume |
| Estimated pharmaceutical sector size |
Approximately US$60 billion |
| Pharmaceutical exports FY26 |
US$31.12 billion |
| Pharmaceutical exports FY25 |
US$30.47 billion |
| FY26 export growth |
Approximately 2.1% |
| Share of global generic medicine supply |
Around 20% |
| Pharmaceutical sector turnover FY25 |
₹4.72 lakh crore |
| Projected industry size by 2030 |
US$130 billion |
Sources: Ministry of Commerce and Industry, Economic Survey 2025–26, Department of Pharmaceuticals and Press Information Bureau.
The US$130 billion figure represents an industry projection rather than a guaranteed future market size.
What Is Supporting India's Pharmaceutical Sector?
Several factors contribute to the industry's development:
-
Domestic healthcare demand: Demand for prescription medicines across chronic and acute therapies supports the Indian formulations market.
-
Global generic medicines: Indian pharmaceutical manufacturers supply generic medicines to international markets.
-
Complex and specialty drugs: Companies are expanding into differentiated formulations, respiratory treatments and innovative therapies.
-
Pharmaceutical outsourcing: API and CDMO manufacturers benefit from outsourced research and manufacturing contracts.
-
Biotechnology: Biosimilars and biologics create opportunities for companies with specialised manufacturing and development capabilities.
However, these drivers affect businesses differently.
For example, a domestic branded formulations company depends heavily on prescriptions, distribution and product mix. A US-focused generic manufacturer depends more on regulatory approvals, competitive pricing and product launches.
As a result, the best Indian pharma stocks cannot be identified using a single industry growth rate.
The following analysis examines the businesses and Q2 FY27 financial performance of 14 major pharmaceutical companies.
Each company has different earnings drivers, operational challenges and financial characteristics.
1. Sun Pharmaceutical Industries (SUNPHARMA)
Sun Pharmaceutical Industries is a major Indian pharmaceutical company with operations across domestic branded formulations, international generics and innovative medicines.
Its diversified business provides exposure to established prescription brands and higher-value specialty products.
Sun Pharma Q2 FY27 Financial Highlights
-
Sales: ₹16,100 crore, up 11.8% YoY.
-
India formulations: ₹5,552.3 crore, up 17.3%.
-
Global innovative medicines: US$356 million, representing 21.1% of reported sales.
-
US formulations: US$455 million, down 8.2%.
-
EBITDA margin: 29.3%.
-
Reported PAT: ₹1,988.5 crore.
-
Adjusted PAT: ₹3,162 crore.
The company's domestic formulations business remained an important growth driver during the quarter.
However, US formulations sales declined, indicating pressure in that part of the business.
A significant difference between reported and adjusted profit resulted from exceptional expenses related to a litigation settlement and costs associated with the proposed acquisition of Organon.
These charges reduced reported profitability, although they should be distinguished from the company's recurring operating performance.
To assess Sun Pharma's market performance alongside its domestic formulations growth and innovative medicines business, check the Sun Pharma Share Price, stock charts and key valuation ratios.
What should investors track?
Investors should monitor global innovative medicine sales, US pricing pressure, research expenditure, specialty drug commercialisation and developments concerning the Organon transaction.
Integration costs and the ability to generate sustainable returns from new medicines will be important for evaluating future profitability.
2. Divi's Laboratories (DIVISLAB)
Divi's Laboratories operates primarily in active pharmaceutical ingredients (APIs), intermediates, nutraceutical ingredients and custom synthesis.
Its business differs from traditional pharmaceutical companies selling branded medicines directly to patients.
The company provides manufacturing capabilities to pharmaceutical customers, making contract execution and capacity utilisation important earnings drivers.
Divi's Laboratories Q2 FY27 Financial Highlights
-
Revenue from operations: ₹3,676 crore, up 35.4% YoY.
-
Total income: ₹3,770 crore.
-
Reported PAT: ₹1,127 crore, up 63.6%.
-
H1 FY27 PAT: ₹2,029 crore.
-
H1 FY27 operating cash flow: ₹384 crore.
The company reported strong quarterly earnings growth.
However, operating cash generation was significantly lower than reported profits during the first half of FY27.
Increases in inventories and trade receivables absorbed substantial working capital, creating a difference between accounting profitability and cash generation.
This is important because pharmaceutical manufacturing businesses often require investment in raw materials, production capacity and customer inventory.
Want to evaluate how Divi's Laboratories' earnings growth compares with its market valuation? Review the Divis Lab share price, historical charts and important financial indicators.
What should investors track?
The important indicators include custom synthesis orders, customer concentration, capacity utilisation, operating margins and working-capital management.
Investors should particularly monitor whether the cash conversion gap narrows in subsequent quarters.
3. Cipla (CIPLA)
Cipla operates across respiratory medicines, cardiovascular therapies, anti-infectives and other pharmaceutical categories.
Its business includes Indian branded formulations, US complex generics, Africa and emerging markets.
Respiratory medicines remain an important area of differentiation for the company.
Cipla Q2 FY27 Financial Highlights
-
Revenue: ₹7,404 crore, down 2.4% YoY.
-
India revenue: ₹3,516 crore, up 12%.
-
North America revenue: ₹1,643 crore, down 19%.
-
EBITDA: ₹1,388 crore.
-
EBITDA margin: 18.7%, compared with 25.0% a year earlier.
-
Reported PAT: ₹878 crore.
Cipla's India business grew during the quarter, but weakness in North America affected consolidated performance.
The decline in EBITDA margin indicates that lower revenue from certain products and changes in the business mix reduced operating profitability.
The approval of generic Advair during Q2 FY27 provides a potential opportunity in the differentiated respiratory portfolio.
However, the actual financial contribution will depend on commercial execution, competition and supply availability.
To assess Cipla's market performance alongside its domestic growth and North American revenue trends, check the Cipla share price, stock charts and key valuation ratios.
What should investors track?
Key indicators include US respiratory product launches, recovery in North American revenue, manufacturing performance, Indian prescription growth and EBITDA margin improvement.
4. Dr. Reddy's Laboratories (DRREDDY)
Dr. Reddy's Laboratories operates in global generics, pharmaceutical services, APIs and branded pharmaceutical markets.
Its major geographic operations include North America, India and emerging markets.
Dr. Reddy's Q2 FY27 Financial Highlights
-
Revenue: ₹8,670.8 crore, down 1.5% YoY.
-
North America revenue: ₹2,489 crore, down 23%.
-
India revenue: ₹1,850.8 crore, up 17%.
-
Emerging markets revenue: ₹2,059.5 crore, up 24%.
-
EBITDA margin: 20.6%, compared with 26.7% a year earlier.
-
Profit attributable to shareholders: ₹925 crore.
The decline in North American revenue was partly associated with a reduced contribution from lenalidomide.
This illustrates how revenue from certain high-value generic products can influence the financial performance of pharmaceutical exporters.
Growth in India and emerging markets partly offset this pressure, but consolidated operating margins declined.
What should investors track?
Investors should examine revenue growth excluding lenalidomide, the US launch pipeline, gross margin recovery, R&D expenditure and the ability of new products to replace declining revenue streams.
5. Lupin (LUPIN)
Lupin operates across branded formulations, respiratory products, complex generics and other pharmaceutical therapies.
The company has substantial exposure to both India and the US market.
Lupin Q2 FY27 Financial Highlights
-
Revenue including other operating income: ₹7,827.3 crore, up 11.1%.
-
Product sales: ₹7,785.5 crore, up 14%.
-
India sales: ₹2,383.6 crore, up 14.7%.
-
US sales: ₹3,020.2 crore, up 9.3%.
-
EBITDA: ₹2,171.2 crore, down 10.7%.
-
EBITDA margin: 27.9%.
-
PAT: ₹1,155.3 crore, down 22.2%.
Lupin's revenue performance remained positive, supported by domestic and international sales.
However, profit declined despite higher product sales.
Increased expenses and a lower benefit from foreign-exchange movements affected profitability compared with the previous year.
Its reported EBITDA margin also includes forex and other income, which investors should consider when comparing recurring operating performance.
Lupin reported a net cash position of approximately ₹3,349 crore as of 30 September 2026.
What should investors track?
Important factors include complex generic launches, US respiratory market share, manufacturing expenses, R&D productivity and operating margins.
The company's balance-sheet position is also relevant when assessing its ability to finance future investments.
6. Torrent Pharmaceuticals (TORNTPHARM)
Torrent Pharmaceuticals focuses primarily on branded prescription medicines, including cardiovascular, gastrointestinal, central nervous system and diabetes therapies.
Its domestic branded formulations business is an important part of its operations.
Torrent Pharma Q2 FY27 Financial Highlights
-
Revenue: ₹4,979 crore, up 50.8% YoY.
-
Revenue from merged JB Chemicals: ₹1,086 crore.
-
Base business revenue: ₹3,893 crore, up 18%.
-
Base India revenue: ₹2,181 crore, up 20%.
-
Operating EBITDA: ₹1,666 crore.
-
Operating EBITDA margin: 33.5%.
-
Reported PAT: ₹534 crore, down 9.6%.
Torrent Pharma recorded one of the highest reported revenue growth rates in the comparison.
However, this increase included the contribution from JB Chemicals following the merger effective 8 July 2026.
The base business grew 18%, making organic performance an important indicator for evaluating underlying demand.
Despite operating EBITDA growth, reported PAT declined, highlighting the importance of examining acquisition-related costs and other expenses below EBITDA.
What should investors track?
Investors should monitor integration progress, operating synergies, organic formulations growth, financing costs, debt and cash generation.
The company's ability to sustain margins while integrating JB Chemicals will remain important.
7. Aurobindo Pharma (AUROPHARMA)
Aurobindo Pharma is a large pharmaceutical exporter with operations across generic formulations, APIs and regulated international markets.
The US and Europe are significant contributors to its business.
Aurobindo Pharma Q2 FY27 Financial Highlights
-
Revenue: ₹10,263 crore, up 23.9% YoY.
-
US revenue: ₹4,555 crore, up 25%.
-
Europe revenue: ₹3,161 crore, up 27%.
-
EBITDA before forex and other income: ₹2,156 crore, up 28.5%.
-
Operating EBITDA margin: 21%.
-
PAT: ₹1,124 crore, up 32.5%.
-
Quarterly free cash flow: US$146 million after strategic capital expenditure.
Aurobindo's quarterly performance reflected growth across its major international markets.
Unlike some other US-exposed pharmaceutical companies, Aurobindo reported strong North American revenue growth during Q2 FY27.
Its EBITDA also grew faster than revenue, indicating improved operating earnings during the quarter.
Positive free cash flow after strategic capital expenditure is another relevant financial indicator.
What should investors track?
Key factors include US launches, European operating profitability, manufacturing compliance, generic pricing pressure and cash generation after expansion expenditure.
8. Zydus Lifesciences (ZYDUSLIFE)
Zydus Lifesciences operates across Indian and international formulations, APIs, consumer wellness, specialty medicines and medical technology.
This diversified business structure provides multiple revenue sources, but also requires investment across different product categories.
Zydus Lifesciences Q2 FY27 Financial Highlights
-
Revenue: ₹7,909.6 crore, up 29.2% YoY.
-
EBITDA: ₹1,894.5 crore, down 6%.
-
EBITDA margin: 24.0%, compared with 32.9% a year earlier.
-
Reported PAT: ₹925.5 crore, down 26.6%.
-
North America formulations growth: 20.8%.
-
India formulations growth: 18.3%.
-
R&D expenditure: ₹657.3 crore, representing 8.3% of revenue.
Zydus reported strong revenue growth across important pharmaceutical markets.
However, operating profit and net profit declined.
The fall in EBITDA margin indicates that revenue expansion was accompanied by a less favourable profitability profile.
Its substantial R&D expenditure also reflects ongoing investment in future products and therapeutic capabilities.
What should investors track?
Investors should monitor operating margin recovery, US product approvals, specialty medicine growth, R&D returns and the performance of consumer wellness operations.
An important question is whether revenue growth can translate into sustainable operating profit growth.
9. Mankind Pharma (MANKIND)
Mankind Pharma has a substantial presence in the Indian pharmaceutical market, supported by prescription medicines, consumer healthcare products and specialty therapies.
Its domestic business remains a significant source of revenue.
Mankind Pharma Q2 FY27 Financial Highlights
-
Revenue: ₹4,338 crore, up 17.3% YoY.
-
Domestic revenue: ₹3,657 crore, up 14.8%.
-
Export revenue: ₹681 crore, up 32.7%.
-
EBITDA: ₹1,175 crore, up 27.2%.
-
EBITDA margin: 27.1%, compared with 25.0% a year earlier.
-
PAT: ₹716 crore, up 37.7%.
Mankind reported growth in both domestic and export operations.
EBITDA growth exceeded revenue growth, while operating margins improved during the quarter.
The company is also expanding its presence in specialty and advanced therapies.
Its integration of Bharat Serums and Vaccines and announced acquisition of Armed Cell Therapeutics introduce additional opportunities alongside capital allocation and execution requirements.
What should investors track?
Investors should assess domestic prescription growth, specialty business profitability, acquisition integration, debt reduction and R&D investment returns.
10. Laurus Labs (LAURUSLABS)
Laurus Labs operates across pharmaceutical CDMO services, APIs and finished dosage formulations.
Its business provides exposure to outsourced pharmaceutical development and commercial manufacturing.
Laurus Labs Q2 FY27 Financial Highlights
-
Revenue: ₹2,206 crore, up 33% YoY.
-
CDMO revenue: ₹904 crore, up 75%.
-
Affordable Medicines revenue: ₹1,302 crore, up 15%.
-
EBITDA: ₹762 crore, up 78%.
-
EBITDA margin: 34.5%, compared with 26.0% a year earlier.
-
PAT: ₹441 crore, up 126%.
The CDMO business was an important contributor to Laurus Labs' quarterly growth.
Higher CDMO revenue supported a substantial improvement in EBITDA and operating margins.
The company has also invested in commercial-scale peptide manufacturing and other specialised capabilities.
These investments can support future manufacturing opportunities, but they require adequate demand and capacity utilisation to generate attractive returns.
What should investors track?
Investors should focus on commercial CDMO orders, customer concentration, new facility commissioning, peptide manufacturing utilisation, capital expenditure and free cash flow.
Sustaining profitability will depend partly on the continued conversion of customer contracts into commercial manufacturing revenue.
11. Alkem Laboratories (ALKEM)
Alkem Laboratories operates across Indian branded formulations, international pharmaceuticals and biotechnology.
Its domestic pharmaceutical business covers several acute and chronic therapeutic categories.
Alkem Laboratories Q2 FY27 Financial Highlights
-
Revenue: ₹4,552 crore, up 13.8% YoY.
-
India sales: ₹3,027.5 crore, up 9.5%.
-
International sales: ₹1,454 crore, up 22.3%.
-
EBITDA: ₹1,025.2 crore, up 11.3%.
-
Profit attributable to shareholders: ₹675.3 crore, down 11.7%.
Alkem reported revenue growth across domestic and international operations.
However, profit attributable to shareholders declined despite higher EBITDA.
The company reported a net cash position of approximately ₹4,905 crore at the end of September 2026.
Its expansion into medical technology, including Occlutech, creates opportunities for diversification while also increasing the importance of integration and capital allocation.
What should investors track?
Key areas include domestic therapy growth, international profitability, R&D productivity, medical technology integration and the effective use of cash reserves.
12. Glenmark Pharmaceuticals (GLENMARK)
Glenmark Pharmaceuticals operates across global formulations, branded generics and innovative pharmaceutical research.
The company has exposure to India, North America, Europe and emerging markets.
Glenmark Pharma Q2 FY27 Financial Highlights
-
Reported revenue: ₹4,247.3 crore, down 29.8% YoY.
-
Like-for-like revenue growth: Approximately 20%.
-
EBITDA: ₹863.8 crore.
-
EBITDA margin: 20.3%.
-
Reported PAT: ₹263.8 crore.
-
Adjusted PAT: ₹485.2 crore.
Glenmark's reported revenue decline does not fully represent the underlying performance of its formulations business.
The company reported approximately 20% like-for-like growth after adjusting for differences in the comparative revenue base and licensing-related income.
However, the difference between reported and adjusted profit is important when evaluating recurring earnings.
Innovation and licensing arrangements can create financial opportunities, but the timing and repeatability of such income require careful assessment.
What should investors track?
Investors should examine recurring formulations revenue, licensing and milestone income, oncology pipeline progress, R&D costs and sustainable operating profitability.
13. Biocon (BIOCON)
Biocon provides exposure to biosimilars, generic medicines and biotechnology research and manufacturing services.
Its consolidated operations also include Syngene International.
Biocon Q2 FY27 Financial Highlights
-
Operating revenue: ₹4,389 crore, up approximately 2.2% YoY.
-
Biosimilars revenue: ₹2,809 crore, up 3%.
-
Generics revenue: ₹774 crore, up 10%.
-
Services revenue: ₹833 crore, down 9% YoY.
-
EBITDA: ₹865 crore.
-
EBITDA margin: 20%.
-
Reported PAT: ₹41 crore, compared with ₹85 crore a year earlier.
-
Interest costs: ₹240 crore, down 12% YoY.
Biocon reported modest revenue growth, but net profitability remained under pressure.
Although interest costs declined, they continued to represent a substantial expense relative to reported profit.
The company also announced a ten-year biosimilar pertuzumab partnership in Brazil valued at approximately US$400 million.
This represents the value of a long-term commercial arrangement, not revenue recognised entirely during Q2 FY27.
What should investors track?
Important indicators include biosimilar approvals, product launches, market adoption, manufacturing yields, debt and finance costs, and Syngene's business performance.
14. Ipca Laboratories (IPCALAB)
Ipca Laboratories operates across domestic branded formulations, international pharmaceutical markets and API manufacturing.
Its business combines Indian prescription medicines with export-oriented pharmaceutical operations.
Ipca Laboratories Q2 FY27 Financial Highlights
-
Revenue: ₹2,909.9 crore, up 13.8% YoY.
-
EBITDA before forex, other income and exceptional items: ₹668.3 crore, up 21%.
-
EBITDA margin: Approximately 23.0%.
-
Profit attributable to shareholders: ₹375.1 crore, up 33%.
-
Indian formulations income growth: 14%.
-
Export income growth: 17%.
The reported growth in domestic formulations and exports supported Ipca's quarterly financial performance.
EBITDA increased faster than revenue, while profit attributable to shareholders also improved.
The Indian formulations and export growth figures are based on standalone business measures.
What should investors track?
Investors should assess domestic formulations performance, export demand, regulatory compliance, operating margins and the contribution from subsidiaries and acquired businesses.
The top pharmaceutical stocks in India do not operate under identical business models.
Some companies generate a substantial portion of revenue from Indian prescription medicines, while others focus on international generic drugs, specialised manufacturing or biotechnology.
Understanding these differences is essential before comparing financial ratios or growth opportunities.
Major Categories of Pharma Stocks in India
-
Indian Branded Formulations
-
Companies: Sun Pharma, Torrent Pharma, Mankind Pharma, Alkem Laboratories and Ipca Laboratories.
-
Key business drivers: Domestic prescription demand, market share, product launches and pricing.
-
US and Global Generics
-
Companies: Dr. Reddy's Laboratories, Aurobindo Pharma, Lupin, Cipla and Zydus Lifesciences.
-
Key business drivers: Regulatory approvals, new product launches, generic competition and international market demand.
-
APIs and Custom Synthesis
-
Companies: Divi's Laboratories and Laurus Labs.
-
Key business drivers: Customer contracts, pharmaceutical outsourcing, manufacturing capacity and plant utilisation.
-
Biosimilars and Biologics
-
Companies: Biocon and Zydus Lifesciences.
-
Key business drivers: Regulatory approvals, commercial adoption, manufacturing capabilities and market expansion.
-
Innovative and Specialty Medicines
-
Companies: Sun Pharma and Glenmark Pharmaceuticals.
-
Key business drivers: Drug development, clinical research, product approvals and successful commercialisation.
-
Diversified Global Formulations
-
Companies: Aurobindo Pharma, Glenmark Pharmaceuticals and Dr. Reddy's Laboratories.
-
Key business drivers: Geographic diversification, product portfolio, international sales and operating profitability.
Some pharmaceutical companies operate across multiple categories. Therefore, investors should evaluate their major revenue segments and financial performance before comparing them with other pharma stocks.
Domestic Branded Formulations Companies
Domestic pharmaceutical businesses depend on prescription volumes, therapeutic demand, doctor coverage, distribution networks and pricing.
Companies such as Sun Pharma, Torrent, Mankind and Alkem have substantial exposure to the Indian formulations market.
However, revenue growth must be evaluated alongside field-force productivity, marketing expenditure, competition and medicine price regulation.
US and Global Generic Drug Manufacturers
Export-oriented companies generate revenue by manufacturing and selling medicines across international markets.
Companies such as Aurobindo, Lupin, Cipla and Dr. Reddy's have significant exposure to the US pharmaceutical market.
Their performance depends on regulatory approvals, competition, manufacturing efficiency and product-level pricing.
Even when sales volumes increase, operating profit may decline if prices fall or high-margin products lose exclusivity.
API and CDMO Companies
API manufacturers supply pharmaceutical ingredients, while CDMO businesses provide contracted development and manufacturing services.
Divi's Laboratories and Laurus Labs represent important listed companies for researching these segments.
Their growth depends on customer relationships, manufacturing technology, contract execution and plant utilisation.
New capacity can improve earnings when demand increases, but it can also increase capital requirements and working-capital pressure.
Biosimilars and Innovative Medicine Companies
Biosimilars are biological medicines developed to be highly similar to approved reference biological products.
Biocon and Zydus provide exposure to this segment, while Sun Pharma and Glenmark have interests in innovative and specialty medicines.
These businesses face additional development, manufacturing, regulatory and commercialisation challenges.
The financial value of a medicine pipeline depends on successful approvals, market acceptance and future cash generation, rather than the number of products under development alone.
Several industry developments influence the earnings outlook for pharmaceutical companies in 2026.
Their impact depends on each company's product portfolio, geographic exposure and investment strategy.
1. Growth in India's Domestic Pharmaceutical Market
Domestic prescription demand remains an important revenue driver for Indian pharmaceutical companies.
Q2 FY27 results showed strong growth across several domestic operations:
-
Sun Pharma: India formulations grew 17.3%.
-
Dr. Reddy's: India revenue grew 17%.
-
Lupin: India sales increased 14.7%.
-
Mankind Pharma: Domestic revenue increased 14.8%.
-
Torrent Pharma: Base India business grew 20%.
These figures demonstrate the contribution of domestic operations to the companies' quarterly performance.
However, investors should distinguish growth arising from prescription volumes, price changes and new product launches.
2. US Generic Medicines and Pricing Pressure
The US pharmaceutical market remains important for several Indian generic medicine manufacturers.
Q2 FY27 showed differences in North American performance.
Aurobindo's US revenue increased approximately 25%, while Dr. Reddy's North American revenue declined 23% and Cipla's declined 19%.
These changes reflect the importance of individual product portfolios, competition, launch timing and the contribution of high-value medicines.
For export-oriented businesses, revenue growth excluding temporary product advantages can provide a clearer picture of underlying performance.
3. Biopharma SHAKTI and Biotechnology Development
The Union Budget 2026–27 announced Biopharma SHAKTI with an outlay of ₹10,000 crore over five years.
The initiative aims to strengthen India's ecosystem for biologics and biosimilars.
Its proposed measures include support for pharmaceutical research, specialised education institutions, manufacturing capabilities and accredited clinical trial sites.
Companies involved in biosimilars, biologics and advanced pharmaceutical manufacturing may benefit from a stronger supporting ecosystem over time.
However, the announcement does not guarantee revenue growth or direct financial assistance for any particular listed pharmaceutical company.
4. Pharmaceutical Outsourcing and CDMO Opportunities
Pharmaceutical outsourcing creates opportunities for companies manufacturing APIs, intermediates, complex molecules and finished formulations.
Laurus Labs reported 75% CDMO revenue growth during Q2 FY27, demonstrating how commercial contract execution can contribute to earnings growth.
Nevertheless, CDMO businesses can experience uneven quarterly revenue because of customer requirements, development cycles and manufacturing schedules.
Investors should therefore examine order conversion, customer concentration and capacity utilisation rather than extrapolating a single quarter's growth rate.
Pharma stocks in India face several risks related to regulatory approvals, drug pricing, manufacturing, competition and financial performance. Investors should understand these factors before evaluating pharmaceutical companies.
1. US Generic Pricing Pressure
Indian pharmaceutical companies operating in the US face competition from other generic drug manufacturers. Falling drug prices can reduce revenue and profit margins.
What to monitor: US product pricing, sales growth and gross margins.
2. Manufacturing and Regulatory Risks
Pharmaceutical manufacturers must comply with strict quality and safety regulations. US FDA observations, warning letters or manufacturing issues can delay product approvals and disrupt supplies.
What to monitor: US FDA inspections, regulatory observations and corrective actions.
3. Patent Expiry and Product Concentration
Some pharmaceutical companies generate substantial profits from a limited number of high-value medicines. When patents or exclusivity periods expire, competition may increase and earnings can decline.
What to monitor: Revenue dependence on major products and upcoming patent expiries.
4. Research and Development (R&D) Risks
Developing new medicines requires significant investment, but not every product receives regulatory approval or achieves commercial success.
What to monitor: R&D expenditure, clinical trial progress and product approvals.
5. Acquisition and Integration Risks
Pharmaceutical acquisitions can expand product portfolios and market presence, but they may also increase debt, operating expenses and integration costs.
What to monitor: Acquisition synergies, financing costs, debt levels and operating cash flow.
6. Currency Fluctuations
Companies earning revenue from international markets are exposed to foreign-exchange movements. Currency fluctuations can affect reported revenue, expenses and profitability.
What to monitor: Constant-currency revenue growth and foreign-exchange gains or losses.
7. Working-Capital Pressure
Higher inventories and trade receivables can reduce operating cash flow even when revenue and reported profit increase.
What to monitor: Inventory levels, receivables, operating cash flow and cash conversion.
8. Drug Pricing Regulations
Government price controls can limit the prices pharmaceutical companies charge for certain medicines, affecting revenue growth and profitability.
What to monitor: Changes in drug pricing regulations and exposure to price-controlled products.
9. Capital-Intensive Expansion
New manufacturing facilities and specialised pharmaceutical capabilities require substantial capital expenditure. If capacity utilisation remains low, these investments can reduce free cash flow and returns on capital.
What to monitor: Capital expenditure, plant utilisation, free cash flow and return on capital employed (ROCE).
Why Earnings Quality Matters
Investors should distinguish temporary financial effects from recurring business problems.
For example, Sun Pharma's exceptional expenses affected reported quarterly profitability. Such items should be examined separately when assessing underlying operations.
However, repeated declines in gross margins, persistent cash-flow weakness or manufacturing disruptions may indicate more fundamental challenges.
Divi's Laboratories provides a different example. Its profit increased strongly, but the H1 FY27 operating cash flow was affected by working-capital requirements.
This does not automatically indicate permanent deterioration, but cash conversion remains an important indicator to track.
Selecting the best pharma stocks requires evaluating both business quality and the valuation at which shares are available.
A company with strong revenue growth and operating margins is not automatically an attractive investment at every share price.
Similarly, a company experiencing temporary earnings pressure may require a different valuation approach from a business facing structural revenue decline.
Important Financial Ratios for Pharma Stocks
| Financial Metric |
Why It Matters |
| Price-to-earnings (P/E) |
Shows the share price relative to earnings; adjust for exceptional items |
| EV/EBITDA |
Compares enterprise value with operating earnings and incorporates debt differences |
| Return on capital employed (ROCE) |
Measures efficiency in generating returns from capital |
| Operating cash flow/PAT |
Indicates how effectively reported profits convert into cash |
| Free cash flow |
Shows cash remaining after capital expenditure |
| Net debt/EBITDA |
Helps evaluate financial leverage |
| R&D/revenue |
Measures investment in future product development |
| EBITDA margin |
Indicates operating profitability |
| Revenue growth |
Measures business expansion and should be separated into organic and acquired growth |
Why P/E Alone Cannot Identify the Best Pharma Stocks
A low P/E ratio does not necessarily indicate that a pharmaceutical stock is undervalued.
Reported earnings may contain temporary licensing income, high-margin products approaching patent expiry or exceptional gains.
Similarly, a company's reported profit may be affected by acquisition expenses, legal settlements or other non-recurring charges.
Investors should consider four important factors:
-
Normalised earnings: Examine reported earnings after identifying clearly disclosed exceptional items without excluding normal business expenses.
-
Earnings sustainability: Assess whether current revenue and profit margins can continue beyond the reporting quarter.
-
Balance-sheet strength: Consider debt, working capital, capital expenditure and acquisition commitments.
-
Valuation: Compare the current share price with realistic earnings expectations, business quality and financial risks.
Which Pharma Stocks Are Best to Buy Based on Valuation?
There is no universal best stock in the pharma sector in India because valuation attractiveness depends on the price paid and the sustainability of future earnings.
Investors screening Indian pharma stocks to buy should use a common market date when comparing share prices and valuation ratios.
For a complete valuation assessment, the following information should be collected:
A consistent 19 November 2026 closing-price snapshot would be appropriate for this research update.
Current share prices, market capitalisations and valuation multiples have not been inserted because they have not been verified on the same measurement basis.
This avoids comparisons using inconsistent market dates or accounting periods.
The latest pharmaceutical earnings indicate that sales growth, profitability and cash generation can move in different directions.
Three observations are particularly relevant when evaluating the sector.
1. Revenue Growth Does Not Always Translate Into Profit Growth
Zydus Lifesciences reported revenue growth of 29.2%, but EBITDA declined 6% and reported PAT fell 26.6%.
Torrent Pharma's reported revenue increased 50.8%, while PAT declined 9.6%. Its headline growth also included the contribution from the merged JB Chemicals business.
Alkem Laboratories recorded 13.8% revenue growth alongside an 11.7% decline in profit attributable to shareholders.
These results show why investors should examine operating costs, product mix, acquisitions and expenses below EBITDA.
2. International Exposure Creates Different Earnings Outcomes
Pharmaceutical exporters do not necessarily experience the same operating conditions simply because they serve similar geographic markets.
During Q2 FY27, Aurobindo reported strong US sales growth, while Dr. Reddy's and Cipla experienced North American revenue declines.
Individual products, competition, regulatory developments and manufacturing efficiency can influence outcomes substantially.
The contribution from high-value products also matters when evaluating sustainable earnings.
3. Cash Flow Is Important for Assessing Growth Quality
Strong quarterly profits do not always translate immediately into operating cash.
Divi's Laboratories reported H1 FY27 PAT of ₹2,029 crore, but operating cash flow was ₹384 crore.
Laurus Labs reported strong operating growth while continuing to invest in manufacturing capabilities.
These cases underline the importance of evaluating working capital, capital expenditure and cash conversion alongside EBITDA and net profit.
The Q2 FY27 results highlight several pharmaceutical companies showing different growth and profitability trends. Investors should focus on whether these companies can sustain their performance in the coming quarters.
-
Laurus Labs: Reported 33% revenue growth and 126% PAT growth, supported by strong CDMO performance. Sustaining margins and converting new capacity into revenue will be important.
-
Aurobindo Pharma: Recorded 23.9% revenue growth, supported by expansion in the US and European markets. New product launches and pricing trends remain key factors.
-
Divi's Laboratories: Reported 35.4% revenue growth and 63.6% PAT growth. However, working-capital requirements and operating cash flow need attention.
-
Mankind Pharma: Delivered 17.3% revenue growth and 37.7% PAT growth. Domestic formulations performance and specialty business expansion will be important.
-
Sun Pharma: Reported 11.8% sales growth, supported by Indian formulations and innovative medicines. Specialty drug performance and exceptional costs remain important considerations.
-
Cipla, Dr. Reddy's and Zydus: These companies face different profitability challenges despite their established pharmaceutical operations. Investors should monitor US market performance, product launches and margin recovery.
The key consideration is not which pharma stock recorded the highest quarterly growth, but which companies can maintain earnings, generate cash and deliver sustainable returns on capital.
The next important financial period for pharmaceutical companies is Q3 FY27, covering October to December 2026.
The results will help investors assess whether the latest operating trends are continuing or changing.
Important indicators include:
-
Domestic formulations growth: Monitor prescription demand, market share and product mix across Sun Pharma, Torrent, Mankind, Lupin and other domestic-focused businesses.
-
US generics performance: Track whether Cipla and Dr. Reddy's report improvement in North American operations and whether Aurobindo maintains its revenue momentum.
-
Operating margin recovery: Assess whether Zydus, Cipla and other companies facing profitability pressure can improve margins.
-
Acquisition integration: Follow Torrent Pharma's JB Chemicals integration, Sun Pharma's Organon transaction and other acquisition-related developments.
-
CDMO order execution: Monitor commercial contracts, capacity utilisation and capital expenditure at Laurus Labs and Divi's Laboratories.
-
Biosimilars and specialty medicines: Track regulatory approvals, product launches and commercialisation progress at Biocon, Zydus and Sun Pharma.
-
Cash flow and debt: Examine operating cash flow, working capital, financing costs and free cash flow across the sector.
-
Regulatory compliance: Follow US FDA inspections, manufacturing observations and corrective actions affecting important facilities.
For investors, the most useful development would be evidence that reported revenue growth is translating into sustainable earnings and cash generation.
A single quarter's performance should therefore be considered alongside longer-term financial trends.
India's pharmaceutical sector in 2026 includes companies with different business models, geographic exposures and earnings drivers.
Sun Pharma provides exposure to Indian branded formulations and innovative medicines, while Cipla, Dr. Reddy's, Lupin and Aurobindo have significant international pharmaceutical operations.
Torrent Pharma, Mankind Pharma, Alkem Laboratories and Ipca Laboratories have meaningful domestic formulations businesses.
Divi's Laboratories and Laurus Labs provide exposure to APIs and outsourced pharmaceutical manufacturing, while Biocon operates in biosimilars and biotechnology.
The Q2 FY27 results demonstrate that revenue growth alone is insufficient for identifying the best pharma stocks in India.
Investors should evaluate business quality, sustainable earnings, operating cash flow, regulatory exposure, capital allocation and valuation before comparing pharmaceutical companies.
The strongest research approach is to compare businesses with similar operating characteristics while assessing whether their financial performance can be sustained over time.
1. Which are the best pharma stocks in India in 2026?
Major pharma stocks in India include Sun Pharma, Divi's Laboratories, Cipla, Dr. Reddy's Laboratories, Lupin, Torrent Pharma, Aurobindo Pharma, Zydus Lifesciences, Mankind Pharma and Alkem Laboratories. The best choice for research depends on the company's business model, profitability, cash flow, financial risks and current valuation.
2. Which are the best pharma stocks in India to buy for the long term?
No single pharmaceutical stock can be identified as the best long-term purchase based only on quarterly results. Investors should compare earnings durability, ROCE, free cash flow, R&D productivity, regulatory compliance and valuation. Sun Pharma, Divi's Laboratories, Cipla, Lupin and other established companies offer different business exposures rather than identical investment characteristics.
3. Which Indian pharma stocks have strong domestic pharmaceutical businesses?
Sun Pharma, Torrent Pharmaceuticals, Mankind Pharma, Alkem Laboratories and Ipca Laboratories have substantial Indian formulations operations. Their performance depends on domestic prescription demand, market share, therapeutic portfolios, pricing and operating efficiency.
4. Which pharma stocks in India operate in APIs and CDMO?
Divi's Laboratories and Laurus Labs are major listed companies for researching APIs, custom synthesis and pharmaceutical contract manufacturing. Their financial performance depends on customer contracts, capacity utilisation, manufacturing capabilities and capital expenditure.
5. What financial ratios should investors check before investing in pharma shares?
Important ratios include P/E, EV/EBITDA, ROCE, EBITDA margin, operating cash flow/PAT and net debt/EBITDA. Investors should also assess free cash flow, R&D spending, revenue concentration, regulatory risks and the sustainability of earnings.